H.C. Wainwright Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Relay Therapeutics (RLAYResearch Report), with a price target of $43.00. The company’s shares closed last Friday at $20.49.

Burns covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, MacroGenics, and BioNTech SE. According to TipRanks, Burns has an average return of -22.7% and a 22.60% success rate on recommended stocks.

Currently, the analyst consensus on Relay Therapeutics is a Strong Buy with an average price target of $38.43, representing an 87.55% upside. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $45.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $36.63 and a one-year low of $12.65. Currently, Relay Therapeutics has an average volume of 1.25M.

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLAY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.

Read More on RLAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More